Search
for

    GlossaryPlasminogen Activator Inhibitor-1

    regulates blood clot breakdown by inhibiting plasminogen conversion enzymes

    Plasminogen Activator Inhibitor-1 (PAI-1) is a protein that regulates the breakdown of blood clots by inhibiting enzymes that convert plasminogen to plasmin, which is responsible for clot degradation. Elevated levels of PAI-1 are associated with an increased risk of thrombosis and various cardiovascular diseases, as it can lead to excessive clot formation.

    Related Terms

    Research

    5 / 434 results

    Community Join

    5 / 1000+ results

      community Best Treatment In The Pipeline?

      in Chat  15 upvotes 1 year ago
      New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

      community Upcoming Setipiprant clinical trials hint at systemic daily dosage

       25 upvotes 9 years ago
      The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

      community Allergan recruiting for Setipiprant trial in the US

       13 upvotes 8 years ago
      The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

      community platelet rich plasma experiences/thoughts?

      in Treatment  3 upvotes 3 years ago
      Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Platelet rich plasma treatment is considered expensive but cheaper than hair transplant.